OakChart

ImmunityBio Inc

IBRXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 1:03 PM ET

6.64-0.11 (-1.63%)
2026-11-11 19:04 CET
Market cap
7,148.62 USD m
Revenue, TTM
182.57 USD m
Net income, TTM
-1,109.65 USD m
Free cash flow, TTM
-296.69 USD m
EPS diluted, TTM
-1.07
P/E
-
Compare

Price

IBRX against its 20, 50 and 200-day averages
2050200miss
6.008.0010.0022.4M44.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IBRXclose 6.6420-day 8.3150-day 8.67200-day 7.976.64

46.6% under the 52-week high of 12.43 on 25 Feb 2026. 52-week low 1.95 on 14 Nov 2025. Last 15 sessions, 40.7% high to low

Profile

IBRX
52-week range, 45% of the way up
1.9512.43

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

IndexRUT
Employees691
IPOJul 28, 2015
Beta0.21
ATR, 14d0.75
Rel volume1.10
Short float31.44%
Insider own62.16%
Inst own19.49%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap7.06B
Enterprise Value8.02B
Income-1.11B
Sales182.57M
Book/sh-1.08
Cash/sh0.31
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees691
IPOJul 28, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S38.66
P/B-
P/C21.11
P/FCF-
EV/EBITDA-
EV/Sales43.93
Quick Ratio4.27
Current Ratio4.27
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.07
EPS next Y-0.34
EPS next Q-0.13
EPS this Y-198.03%
EPS next Y69.98%
EPS next 5Y-
EPS past 3/5Y28.42% 15.60%
Sales past 3/5Y678.62% 299.74%
EPS Y/Y TTM-162.88%
Sales Y/Y TTM121.15%
EPS Q/Q-145.21%
Sales Q/Q52.34%
EarningsNov 09 BMO
EPS/Sales Surpr.-157.14% -17.53%

Ownership

Insider Own62.16%
Insider Trans-0.08%
Inst Own19.49%
Inst Trans5.63%
ROA-196.68%
ROE-
ROIC-779.06%
Gross Margin89.73%
Oper. Margin-150.16%
Profit Margin-607.79%
SMA20-20.12%
SMA50-23.48%
SMA200-16.75%
Trades-

Technical

Shs Outstand1.06B
Shs Float401.04M
Short Float31.44%
Short Ratio10.45
Short Interest126.08M
52W High12.43 -46.62%
52W Low1.95 240.26%
Volatility10.94% 8.79%
ATR (14)0.75
RSI (14)35.94
Beta0.21
Rel Volume1.10
Avg Volume12.06M
Volume7,535,165

Performance

Perf Week-25.70%
Perf Month-32.30%
Perf Quarter-13.27%
Perf Half Y-18.59%
Perf YTD235.10%
Perf Year210.05%
Perf 3Y113.34%
Perf 5Y-15.15%
Perf 10Y-12.35%
Recom1.00
Target Price14.25
Prev Close6.74
Price6.64
Change %-1.63%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Mar 12, 2026ResumedBBTIG ResearchBuy$13+95.9%
May 20, 2025UpgradePPiper SandlerNeutral → Overweight$5-24.6%
Mar 06, 2025InitiatedHH.C. WainwrightBuy$8+20.6%
Jan 10, 2025InitiatedBBTIG ResearchBuy$6-9.6%
May 12, 2023DowngradePPiper SandlerOverweight → Neutral$10 → $4-39.7%
Aug 03, 2022InitiatedJJefferiesBuy$8+20.6%

Peers

Mkt cap
TickerCompanyMkt cap
CGONCg Oncology Inc6.56B
URGNUroGen Pharma Ltd1.27B
ENGNenGene Therapeutics Inc118.62M
TARAProtara Therapeutics Inc164.09M
IOVAIovance Biotherapeutics Inc3.75B
BNTXBioNTech SE ADR21.68B
JNJJohnson & Johnson668.87B
NKTRNektar Therapeutics1.31B
ARTVArtiva Biotherapeutics Inc201.94M
MRKMerck & Co Inc360.22B

Insider trading

latest 14 of 45
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Simon Barry J.DirectorOct 05 '26Sale10.7525,000268,7602,777,788Oct 06 06:06 PM
Cohen CherylDirectorOct 02 '26Option Exercise2.9855,979166,817181,365Oct 06 06:05 PM
Cohen CherylDirectorOct 02 '26Sale10.5081,056851,088100,309Oct 06 06:05 PM
Simon Barry J.OfficerOct 05 '26Proposed Sale13.67560,0007,657,760Oct 05 10:21 AM
CHERYL COHENDirectorOct 02 '26Proposed Sale9.2881,056752,200Oct 02 04:26 PM
Cohen CherylDirectorJul 02 '26Option Exercise2.9855,979166,817256,596Jul 06 08:26 PM
Cohen CherylDirectorJul 02 '26Sale9.50131,2101,246,941125,386Jul 06 08:26 PM
Selecky ChristobelDirectorJul 01 '26Option Exercise2.99159,478476,489159,478Jul 06 08:25 PM
Selecky ChristobelDirectorJul 01 '26Sale9.02159,4781,439,0660Jul 06 08:25 PM
CHERYL L COHENOfficerJul 02 '26Proposed Sale9.20131,2101,207,132Jul 02 04:31 PM
Selecky ChristobelDirectorJun 29 '26Option Exercise2.9495,722281,38795,722Jul 01 05:04 PM
Selecky ChristobelDirectorJun 30 '26Option Exercise2.981,0002,9831,000Jul 01 05:04 PM
Selecky ChristobelDirectorJun 29 '26Sale9.0195,722862,2160Jul 01 05:04 PM
Selecky ChristobelDirectorJun 30 '26Sale9.001,0009,0000Jul 01 05:04 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 103
  • New U.S. Survey of Military Service Members and Veterans with Non-Muscle Invasive Bladder Cancer Reveals 53% Were Diagnosed at Age 50 or Younger and Barriers to Care (Business Wire)
  • ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026 (Business Wire) -5.13%
  • ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment (Proactive) -17.66%
  • IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss Retail Says No Way To Escape Further Dilution (Stocktwits)
  • ImmunityBio: Q3 Earnings Snapshot (Associated Press)
  • Loading…
  • ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million (Business Wire)
  • ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ (Business Wire)
  • ImmunityBio Announces ANKTIVA Plus BCG Meets Primary Endpoint in BCG-Nave Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial (Business Wire)
  • Barclays, Deutsche Bank Reveal Stakes In Retail-Favorite Cancer Stocks SLS, IBRX And IOVA Geode Adds More (Stocktwits)
  • ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG Retail Calls It A Great Opening Act For Q3 Earnings (Stocktwits) +7.72%
  • IBRX Stock Climbs Overnight: Founder Calls Sepsis Push Unstoppable As Trials Near Teases NantX After Crypto Heist (Stocktwits)
  • SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus (Stocktwits)
  • SLS, IOVA, IBRX Slump In October As Biotech Stocks Hold Steady: Virginia Pension Fund Raised Stakes In All 3 (Stocktwits) -5.15%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.180-0.070-0.18048.8459.234
2026Q22026-08-04-0.220-0.080-0.21951.2449.704
2026Q12026-05-07-0.620-0.071-0.61644.2143.075
2025Q42026-02-23-0.060-0.077-0.06338.2938.365
2025Q32025-11-05-0.070-0.107-0.07132.0631.885
2025Q22025-08-05-0.100-0.108-0.10426.4323.155
2025Q12025-05-12-0.150-0.128-0.15216.5215.985
2024Q42025-03-03-0.090-0.200-0.0937.559.634
2024Q32024-11-12-0.140-0.178-0.1446.112.933
2024Q22024-08-05-0.199-0.160-0.1961.0314.712
2024Q12024-05-07-0.200-0.195-0.1990.000.062
2023Q42024-02-27-0.360-0.180-0.3480.120.031
2023Q32023-11-10-0.190-0.255-0.1920.080.002
2023Q22023-08-09-0.235-0.235-0.3150.000.002
2023Q12023-05-11-0.270--0.2720.40--
2022Q42023-03-01-0.270-0.220-0.2680.070.031

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.700-0.740-0.6980.000.10
2020FY-0.890-0.770-0.8920.110.11
2021FY-0.890-1.350-0.8910.930.57
2022FY-1.040-1.000-1.0420.200.19
2023FY-1.150-0.930-1.1470.610.51
2024FY-0.620-0.800-0.61914.7521.23
2025FY-0.380-0.386-0.380113.29113.3
2026FY--1.133--200.87
2027FY--0.340--360.16
2028FY-0.120--821.45
2029FY-0.655--1,527
2030FY-1.340--2,524

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-0940456.7354.3058.60
2026Q4S2026-10-1442072.0462.1592.80
2026Q4S2026-10-1341071.5962.1591.00
2026Q4S2026-09-2341071.2160.6591.00
2026Q4S2026-08-0442071.2160.6591.00
2026Q4S2026-07-2341070.5257.6590.70
2026Q4S2026-07-2130071.3057.6590.70
2026Q4S2026-06-1131071.3057.6590.70
2026Q4S2026-05-2641065.1546.7090.70
2026Q4S2026-05-1652069.4646.7090.70
2026Q4S2026-05-0753069.4646.7090.70
2026Q4S2026-05-0651063.7946.7085.71
2026Q4S2026-04-0951163.7946.7085.71
2026Q4S2026-04-0851163.7946.7085.71

Estimate history

EPS, annual-1.2-1.216-0.698-0.892-0.891-1.042-1.147-0.619-0.382-1.0723
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.144-0.093-0.152-0.104-0.071-0.063-0.616-0.219-0.174
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.0450.0470.0430.1110.9340.240.62214.745113.288182.57
Period201720182019202020212022202320242025TTM
Sales, quarterly6.1067.55216.51726.42532.06138.28544.20651.2448.841
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual79.02279.08898.46108.727397.83421.569670.867852.9041011.81063.766
Period201720182019202020212022202320242025MRQ
Shares, quarterly696.831852.904853.556915.625984.9651011.81047.3411053.2221063.766
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue182.57113.2914.740.620.240.930.110.040.05
Cost of Goods Sold Incl. D&A18.7516.2817.5518.5124.19-9.159.01-
Gross Profit163.8297.01-2.81-17.89-23.95--9.04-8.97-
Selling, General and Administrative Excl. Other437.98353.04341.37343.47326.67312.0982.5957.9488.88
Research and Development262.60216.56188.14213.85229.89195.9664.4848.8853.42
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-274.16-256.03-344.18-361.36-350.62-330.28-91.63-66.91-98.39
Interest Expense118.92112.53154.33129.2065.0015.340.900.020.43
Unusual Expense720.54-12.71-76.2786.28-8.594.620.000.90-
Net Income Before Taxes-1,109.84-351.61-413.64-583.89-417.29-349.84-92.38-65.89-96.73
Income Taxes-0.13-0.140.00-0.040.030.010.01-0.10-0.50
Consolidated Net Income-1,109.71-351.47-413.64-583.85-417.32-349.85-92.38-65.79-96.23
Net Income From Continuing Operations-1,109.65-351.40-413.56-583.20-416.57-346.79-92.38-65.79-96.23
Net Income-1,109.65-351.40-413.56-583.20-416.57-346.79-92.38-65.79-96.23
EPS (Recurring)-0.57-0.39-0.70-1.03-1.06-0.88-0.89-0.69-1.22
EPS (Basic, Before Extraordinaries)-1.07-0.38-0.59-1.15-1.04-0.89-0.89-0.70-1.22
EPS (Diluted)-1.07-0.38-0.62-1.15-1.04-0.89-0.89-0.70-1.22
EBITDA-257.62-240.50-326.63-342.85-326.43-311.16-82.48-57.90-88.83
Non-Operating Income (Expense)3.784.238.59-7.05-10.260.390.151.942.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense28.8129.0834.4338.8431.7441.741.562.0818.47
Price To Sales Ratio54.8216.08121.614,105.078,447.902,533.7712,435.448,303.631,953.05
Gross Margin89.7385.63-19.05-2,876.21-9,980.00--8,140.54-20,858.14-
Operating Margin-150.16-226.00-2,334.23-58,097.11-146,090.42-35,361.88-82,545.95-155,597.67-209,338.30
Net Margin-607.79-310.18-2,804.77-93,761.41-173,569.58-37,129.55-83,227.93-152,997.67-204,736.17
Shares Outstanding1,063.771,011.80852.90670.87421.57397.83108.7398.4679.09
Market Capitalization7,148.627,148.621,869.223,351.882,075.632,417.381,447.60372.8191.90

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue48.8451.2444.2138.2832.0626.4316.527.55
Cost of Goods Sold Incl. D&A5.184.714.624.254.134.023.894.14
Gross Profit43.6646.5339.5934.0427.9322.4112.633.41
Selling, General and Administrative Excl. Other121.65108.23109.3898.7283.5693.6977.0672.81
Research and Development71.5460.8266.8963.3650.7354.7447.7334.72
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-77.99-61.70-69.79-64.68-55.63-71.28-64.43-69.40
Interest Expense32.0231.2428.4627.1927.5828.8828.8637.57
Unusual Expense77.92140.85530.93-29.15-14.03-6.9937.45-46.49
Net Income Before Taxes-184.56-230.39-632.79-62.09-67.31-92.31-129.90-59.18
Income Taxes0.000.000.01-0.14-0.040.27-0.230.00
Consolidated Net Income-184.56-230.39-632.80-61.96-67.27-92.57-129.67-59.18
Net Income From Continuing Operations-184.55-230.38-632.78-61.94-67.25-92.56-129.65-59.16
Net Income-184.55-230.38-632.78-61.94-67.25-92.56-129.65-59.16
EPS (Recurring)-0.12-0.13-0.25-0.08-0.08-0.11-0.12-0.14
EPS (Basic, Before Extraordinaries)-0.17-0.22-0.62-0.06-0.07-0.10-0.15-0.08
EPS (Diluted)-0.17-0.22-0.62-0.06-0.07-0.10-0.15-0.09
EBITDA-74.10-57.29-65.41-60.82-51.68-67.41-60.60-65.26
Non-Operating Income (Expense)3.363.40-3.600.631.880.880.851.31
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.726.736.456.917.017.627.539.04
Price To Sales Ratio54.8255.4555.8717.3028.2141.4382.25127.53
Gross Margin89.3990.8289.5588.9187.1284.8076.4745.21
Operating Margin-159.68-120.41-157.88-168.95-173.51-269.76-390.08-918.96
Net Margin-377.86-449.61-1,431.44-161.80-209.77-350.26-784.92-783.40
Shares Outstanding1,063.771,053.221,047.341,011.80984.97915.63853.56852.90
Market Capitalization7,148.629,169.557,885.601,950.232,325.332,330.122,568.861,869.22

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments242.82149.81266.46107.18317.1266.2151.6574.15128.15
Short Term Receivables42.622.653.171.891.330.040.3012.171.26
Inventories0.918.270.000.000.000.000.000.000.00
Other Current Assets28.5323.8524.4531.5015.909.243.802.463.05
Total Current Assets314.88184.59294.08140.58334.3575.5055.7688.77132.46
Net Property, Plant & Equipment147.54170.46182.68189.58119.1767.3972.2376.8976.73
Total Investments and Advances0.701.181.230.840.828.0310.9314.3838.28
Long-Term Note Receivable9.787.136.886.636.38----
Intangible Assets13.9515.9317.0920.001.42--0.562.83
Other Assets15.043.642.494.726.780.944.211.350.15
Total Assets501.90382.93504.45362.36468.91151.86143.12181.95250.44
Short Term Debt Incl. Current Port. of LT Debt9.298.716.78436.05302.256.923.960.960.62
Accounts Payable6.986.729.2021.0211.424.101.752.795.87
Other Current Liabilities45.4939.5142.3043.8055.3313.635.8523.5014.38
Total Current Liabilities61.7554.9458.28500.86369.0024.6511.5627.2620.87
Long Term Debt835.38781.10876.89289.29343.429.8110.885.956.65
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities----0.16---0.50
Other Liabilities104.3435.01155.2122.030.250.000.002.743.58
Total Liabilities1,001.47871.061,090.39812.18712.8234.4722.4435.9431.60
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-500.47-489.10-586.99-447.33-242.17117.39120.68146.01218.84
Total Shareholders Equity-500.47-489.10-586.99-447.33-242.17117.39120.68146.01218.84
Accumulated Minority Interest0.900.971.05-2.49-1.740.000.000.000.00
Total Equity-499.57-488.13-585.94-449.82-243.91117.39120.68146.01218.84
Total Liabilities & Stockholders Equity501.90382.93504.45362.36468.91151.86143.12181.95250.44
Book Value Per Share-0.49-0.57-0.87-1.06-0.611.081.231.852.77
Tangible Book Value Per Share-0.51-0.59-0.90-1.11-0.611.081.231.842.73
Full-Time Employees691680628725587171148161139
Price to Book Ratio-6.26-2.39-8.14-4.76-9.9912.353.090.631.50
Return on Assets-79.43-93.21-134.56-100.22-111.73-62.64-40.48-44.51-33.96
Return on Equity------77.61-49.34-52.75-37.65
Return on Invested Capital-104.92-141.63-201.17--342.53-72.62-50.01-63.33-42.76
Quick Ratio5.083.215.050.280.913.064.823.266.35
Current Ratio5.103.365.050.280.913.064.823.266.35

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-1,109.71-351.47-413.64-583.85-417.32-349.85-92.38-65.79-96.23
Depreciation16.5415.5317.5518.5124.1919.129.159.019.55
Other Funds (Non Cash)811.7285.3424.28194.6163.6275.437.536.3524.34
Funds from Operations-281.45-250.61-371.81-370.73-329.51-255.31-75.71-50.43-62.83
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-6.11-54.33-19.423.98-8.00-19.115.25-10.94-0.55
Cash from Operating Activities-287.56-304.94-391.24-366.76-337.51-274.42-70.45-61.36-63.38
Capital Expenditures-9.53-4.25-6.89-30.58-99.39-33.56-2.64-4.18-13.10
Net Assets From Acquisitions0.000.00-1.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.0020.500.000.000.41
Purchase or Sale of Investments-94.06-145.55-4.360.11126.69-71.82-17.9525.6469.79
Purchase of Investments-468.45-241.37-140.97-10.36-35.31-141.75-91.57-86.62-95.49
Sale Or Maturity of Investments374.3995.82136.6110.47162.0069.9373.62112.26165.28
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-103.59-149.80-12.25-30.4727.30-84.89-20.5921.4657.10
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock381.99400.78190.20110.4060.50169.9987.4838.72-0.17
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00-0.50-0.23
Sale of Common Pref Stock381.99400.78190.20110.4060.50169.9987.4839.220.06
Proceedsfrom Stock Options378.99400.56184.64110.1060.43168.5686.300.000.00
Issuance or Reduction of Debt, Net4.821.7296.89451.39174.12338.500.000.00-0.48
Change in Long Term Debt4.821.7296.89451.39174.12338.500.000.00-0.48
Issuance of Long Term Debt6.002.8896.96451.46174.12338.500.000.000.00
Reduction of Long Term Debt-1.18-1.16-0.06-0.080.000.000.000.00-0.48
Net Financing Active Other Cash Flow-10.52-2.27-5.46-3.44-1.01-3.05-0.50-0.13-0.12
Other Financing Activities Uses-10.52-2.27-5.46-3.44-1.01-4.48-0.50-0.13-0.12
Cash from Financing Activities376.30400.24281.63558.34233.61505.4486.9738.59-0.77
Exchange Rate Effect-0.120.01-0.02-0.290.280.05---
Net Change in Cash-14.98-54.48-121.88160.82-76.31146.19-4.07-1.31-7.05
Free Cash Flow-296.69-308.78-398.12-397.34-415.67-307.98-73.09-65.54-76.48
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.00-0.00-0.010.000.00-0.50

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments334.33357.37380.88242.82257.81153.66
Short Term Receivables53.6153.5043.2742.6232.0322.33
Inventories0.011.940.550.916.706.64
Other Current Assets30.8426.1728.2528.5332.9525.50
Total Current Assets418.79438.98452.95314.88329.50208.13
Net Property, Plant & Equipment142.66145.49146.07147.54163.08168.03
Total Investments and Advances11.2811.2810.000.700.700.70
Intangible Assets10.7611.8412.8813.9514.4714.98
Other Assets25.9020.9224.7215.043.922.98
Total Assets609.39628.50646.64501.90518.99402.08
Short Term Debt Incl. Current Port. of LT Debt7.377.568.569.299.927.44
Accounts Payable13.8412.0011.196.985.777.42
Other Current Liabilities76.8857.1648.2045.4941.4435.78
Total Current Liabilities98.0976.7367.9561.7557.1350.64
Long Term Debt1,288.731,220.841,116.05835.38851.32835.23
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities368.02376.70331.77104.34133.9486.03
Total Liabilities1,754.831,674.271,515.761,001.471,042.40971.89
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-1,146.29-1,046.63-870.01-500.47-524.32-570.75
Total Shareholders Equity-1,146.29-1,046.63-870.01-500.47-524.32-570.75
Accumulated Minority Interest0.850.870.880.900.910.93
Total Equity-1,145.44-1,045.76-869.13-499.57-523.41-569.82
Total Liabilities & Stockholders Equity609.39628.50646.64501.90518.99402.08
Book Value Per Share-1.08-0.99-0.83-0.49-0.53-0.62
Tangible Book Value Per Share-1.09-1.00-0.84-0.51-0.55-0.64
Full-Time Employees---691--
Price to Book Ratio-6.26-10.54-15.51-3.72-3.95-3.81
Return on Assets-196.68-192.58-179.83-79.43-78.91-86.74
Return on Invested Capital-129.57-132.24-257.19-18.50-20.57-35.00
Quick Ratio4.275.706.665.085.653.98
Current Ratio4.275.726.675.105.774.11

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-184.56-230.39-632.80-61.96-67.27-92.57
Depreciation3.894.414.383.873.953.88
Other Funds (Non Cash)96.13159.90553.562.126.7514.50
Funds from Operations-84.54-66.08-74.86-55.97-56.58-74.19
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital9.21-0.41-0.50-14.41-12.33-5.55
Cash from Operating Activities-75.33-66.49-75.36-70.38-68.91-79.75
Capital Expenditures-2.93-3.54-1.79-1.27-0.78-1.08
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-5.12-103.93-29.8644.85-180.59-15.06
Purchase of Investments-109.52-164.22-149.09-45.63-180.59-15.06
Sale Or Maturity of Investments104.4060.29119.2390.470.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-8.04-107.47-31.6543.57-181.36-16.14
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock50.8545.66231.7453.74173.68173.14
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock50.8545.66231.7453.74173.68173.14
Proceedsfrom Stock Options49.4844.99230.7753.74173.68173.14
Issuance or Reduction of Debt, Net3.05-0.010.051.74-0.01-0.00
Change in Long Term Debt3.05-0.010.051.74-0.01-0.00
Issuance of Long Term Debt3.060.000.062.880.000.00
Reduction of Long Term Debt-0.01-0.01-0.01-1.14-0.01-0.00
Net Financing Active Other Cash Flow-0.86-1.21-7.86-0.59-0.15-0.32
Other Financing Activities Uses-0.86-1.21-7.86-0.59-0.15-0.32
Cash from Financing Activities53.0344.44223.9354.89173.52172.81
Exchange Rate Effect-0.24-0.000.120.01-0.060.08
Net Change in Cash-30.59-129.52117.0428.09-76.8177.00
Free Cash Flow-78.26-70.03-77.15-71.25-69.68-80.83

Revenue breakdown

Product2024: 14.15M 2025: 112.98M
Product and Service, Other2024: 595.00K 2025: 306.00K
Europe2024: 531.00K 2025: 278.00K
United States2024: 14.21M 2025: 113.01M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3031.44%126.1M401.0M11.45M
2026-10-1530.66%122.9M401.0M10.96M
2026-09-3030.95%124.1M401.0M9.92M
2026-09-1531.27%125.4M401.0M10.05M
2026-08-3131.33%125.6M401.0M10.61M
2026-08-1432.43%127.5M393.1M11.95M
2026-07-3132.81%129.0M393.2M12.65M
2026-07-1534.59%134.4M388.6M13.45M
2026-06-3033.93%131.8M388.6M14.16M
2026-06-1534.80%135.1M388.3M16.65M
2026-05-2935.13%132.1M376.1M19.01M
2026-05-1535.30%132.8M376.1M24.68M
2026-04-3036.72%138.1M376.1M26.39M
2026-04-1538.01%140.3M369.2M37.78M
2026-03-3139.32%135.5M344.7M39.13M
2026-03-1338.93%134.2M344.7M36.28M
2026-02-2738.42%132.4M344.7M33.99M
2026-02-1339.07%134.7M344.7M27.01M
2026-01-3040.85%135.2M330.9M24.88M
2026-01-1538.38%127.0M330.9M13.14M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.005.405.905.6423.79271.0042.000.988-0.0620.000
call2.004.404.804.5212.98212.002.000.979-0.0630.000
call3.003.403.803.649.0076.005.000.968-0.0600.000
call3.502.853.303.087.3969.004.000.961-0.0590.000
call4.002.452.852.656.41940.003.000.953-0.0560.000
call4.501.852.502.246.7076.001.000.943-0.0540.001
call5.001.352.051.886.1203130.000.927-0.0500.001
call5.500.851.601.505.16312.000.000.904-0.0450.001
call6.000.351.101.203.94526.000.000.802-0.0620.001
call6.500.250.350.301.42239094.000.603-0.0670.002
call7.000.050.100.091.1899395460.309-0.0570.002
call7.500.000.050.041.50149831.000.140-0.0410.001
call8.000.000.050.031.89994915.000.116-0.0460.001
call8.500.000.050.102.4106520.000.095-0.0490.001
call9.000.000.050.032.8001,3011520.086-0.0550.001
call9.500.000.100.043.16459220.000.078-0.0570.001
call10.000.000.500.023.5114970.000.072-0.0600.001
call10.500.000.550.103.8551090.000.067-0.0610.001
call11.000.000.100.054.0226630.000.064-0.0600.001
call11.500.000.050.654.22425.000.000.061-0.0610.001
call12.000.000.050.153.7982140.000.059-0.0470.001
call12.500.001.100.054.88141.000.000.056-0.0670.001
call13.000.000.500.065.0901270.000.054-0.0690.001
call13.500.002.100.005.1070.000.000.053-0.0670.001
call14.000.000.950.585.4751.000.000.051-0.0710.001
call14.500.001.150.005.7240.000.000.050-0.0720.001
call15.000.000.950.005.8430.000.000.049-0.0730.000
call15.500.000.750.006.0410.000.000.047-0.0740.000
call16.000.002.100.006.2150.000.000.046-0.0750.000
call16.500.000.750.006.3820.000.000.046-0.0760.000
call17.000.000.750.006.5880.000.000.045-0.0760.000
call17.500.000.750.006.6970.000.000.044-0.0770.000
call18.000.000.750.006.8910.000.000.043-0.0770.000
call19.000.000.750.007.1730.000.000.042-0.0790.000
call20.000.000.950.007.3980.000.000.041-0.0810.000
put1.000.002.150.0015.3280.000.00-0.012-0.0610.000
put2.000.002.150.009.8240.000.00-0.021-0.0630.000
put3.000.000.050.005.7370.000.00-0.031-0.0430.000
put3.500.000.050.004.7710.000.00-0.038-0.0410.000
put4.000.000.300.004.5210.000.00-0.048-0.0550.000
put4.500.000.750.004.9530.000.00-0.106-0.1100.001
put5.000.000.050.002.8090.000.00-0.075-0.0480.001
put5.500.000.050.052.1031192.00-0.097-0.0450.001
put6.000.000.100.041.75776.0051.00-0.201-0.0620.001
put6.500.000.200.121.376318117-0.397-0.0660.002
put7.000.300.550.451.7101,45913.00-0.691-0.0570.002
put7.500.651.000.842.1552347.00-0.857-0.0400.001
put8.001.252.501.455.65627341.00-0.887-0.0460.001
put8.501.552.001.873.2697321.00-0.903-0.0500.001
put9.002.202.602.454.47757.0035.00-0.914-0.0540.001
put9.502.203.502.787.42925.0032.00-0.922-0.0560.001
put10.003.203.603.445.34472.0043.00-0.928-0.0590.001
put10.503.704.204.006.43233.002.00-0.932-0.0610.001
put11.004.104.704.106.9962.000.00-0.936-0.0620.001
put11.504.305.305.017.9918.003.00-0.939-0.0640.001
put12.004.805.805.518.3273.002.00-0.941-0.0650.001
put12.505.107.900.0013.0000.000.00-0.944-0.0670.001
put13.005.607.106.5810.7353.000.00-0.946-0.0680.001
put13.506.108.807.3715.2661.000.00-0.947-0.0690.001
put14.005.309.400.0012.8550.000.00-0.949-0.0700.001
put14.507.508.407.9210.3881.004.00-0.950-0.0710.001
put15.007.608.808.379.9910.004.00-0.951-0.0720.000
put15.508.1010.909.0218.8541.000.00-0.953-0.0730.000
put16.008.6011.300.0019.0910.000.00-0.954-0.0740.000
put16.509.2011.7010.1519.3243.000.00-0.954-0.0740.000
put17.0010.0012.4011.0019.5543.003.00-0.955-0.0750.000
put17.5010.1012.8011.0017.1844.005.00-0.956-0.0760.000
put18.0010.2012.4011.4514.8470.002.00-0.957-0.0760.000
put19.0011.1013.5012.5219.3315.0040.00-0.958-0.0780.000
put20.0012.3014.4013.4915.4713.0040.00-0.959-0.0790.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-05SEC
2026-10-064Statement of changes in beneficial ownership of securities2026-10-02SEC
2026-10-05144Filing for proposed sale of securities under Rule 144.SEC
2026-10-02144Filing for proposed sale of securities under Rule 144.SEC
2026-08-06SCHEDULE 13D/ASEC
2026-08-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-048-KCurrent report2026-08-04SEC
2026-07-308-KCurrent report2026-07-29SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-02SEC
2026-07-02144Filing for proposed sale of securities under Rule 144.SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-30144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-09SEC
2026-06-108-KCurrent report2026-06-09SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-04SEC
2026-06-04144Filing for proposed sale of securities under Rule 144.SEC
2026-05-188-KCurrent report2026-05-14SEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-10001.12M2
2026-090000
2026-080000
2026-07002.69M2
2026-06001.23M4
2026-050000
2026-040000
2026-030000
2026-02002.93M4
2026-01001.53M3
2025-120000
2025-110000

Institutional holders

Manager% owned
BlackRock, Inc.3.25%
STATE STREET CORP2.04%
VANGUARD PORTFOLIO MANAGEMENT LLC1.71%
VANGUARD CAPITAL MANAGEMENT LLC1.50%
D. E. Shaw & Co., Inc.1.10%
TWO SIGMA INVESTMENTS, LP1.06%
GEODE CAPITAL MANAGEMENT, LLC1.00%
MILLENNIUM MANAGEMENT LLC0.53%
UBS Group AG0.36%
NORTHERN TRUST CORP0.34%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF1.19%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.11%
iShares Russell 2000 ETF0.95%
VANGUARD SMALL-CAP INDEX FUND0.80%
VANGUARD SMALL-CAP GROWTH INDEX FUND0.46%
Fidelity Small Cap Index Fund0.40%
VANGUARD EXTENDED MARKET INDEX FUND0.36%
iShares Russell 2000 Growth ETF0.34%
iShares Biotechnology ETF0.25%
VANGUARD RUSSELL 2000 INDEX FUND0.21%

OakChart. IBRX. Cached 15 minutes.